Literature DB >> 16202683

Stem cell dysregulation in myelofibrosis with myeloid metaplasia: current data on growth factor and transcription factor involvement.

Marie-Claire Martyré1, Marie-Caroline Le Bousse-Kerdilès.   

Abstract

Myelofibrosis with myeloid metaplasia (MMM), the rarest Philadelphia chromosome-negative chronic myeloproliferative disorder (MPD), is characterized by extramedullary hematopoiesis and myelofibrosis. The primary molecular defect leading to the clonal amplification of the hematopoietic progenitors is still unknown. In this review, we will focus on current data in favor of a pivotal role for hematopoietic and fibrogenic growth factors and of transcription factors in the dysregulation of the hematopoietic compartment. These data shed novel insight into the genesis of MMM myeloproliferation and led us to propose a model, integrating alterations in the expression and function of nuclear regulatory factors and in the hierarchical and complex network of interactions between hematopoietic cells and stroma in the pathogenetic mechanisms of the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16202683     DOI: 10.1053/j.seminoncol.2005.04.009

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  2 in total

1.  Regulation of C/EBPbeta isoforms by MAPK pathways in HL60 cells induced to differentiate by 1,25-dihydroxyvitamin D3.

Authors:  Ewa Marcinkowska; Edward Garay; Elzbieta Gocek; Agnieszka Chrobak; Xuening Wang; George P Studzinski
Journal:  Exp Cell Res       Date:  2006-04-19       Impact factor: 3.905

2.  Primary myelofibrosis and the "bad seeds in bad soil" concept.

Authors:  Marie-Caroline Le Bousse-Kerdilès
Journal:  Fibrogenesis Tissue Repair       Date:  2012-06-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.